Global and China Stem Cell Industry Report, 2015-2018
  • Nov.2015
  • Hard Copy
  • USD $2,600
  • Pages:120
  • Single User License
    (PDF Unprintable)       
  • USD $2,400
  • Code: ZYM071
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,800
  • Hard Copy + Single User License
  • USD $2,800

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research.

Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out.

Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia.

Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies.

In February 2015, Ministry of Science and Technology of the People’s Republic of China published the Stem Cell and Translational Medicine Implementation Plan of National Key R&D Program (Draft). In August 2015, CFDA (China Food and Drug Administration) issued Management on Clinical Stem Cell Experimental Study (Trial). With the relaxation of policies, the stem cell industry has attracted Chinese investors once again.

On December 4, 2014, Xi'an International Medical Investment (formerly known as Kaiyuan Investment) announced to invest RMB270 million in acquiring 34% stake in H & B’s registered capital in order to accelerate the development of health care services and foster new profit engines.

On April 17, 2015, Yinhe Investment proclaimed that it would associate with its controlling shareholder Yinhe Group to jointly lavish RMB2 billion in the establishment of Biomedical M&A Fund whose total size hits RMB6 billion. The fund is mainly used for immunotherapy, stem cell clinical application platforms, macromolecular drugs, antibody drug development and other fields.

On October 27, 2015, Ningxia Xinri Hengli Steel Wire Rope Co., Ltd. released a restructuring plan to take over 80% stake in BoyaLife from Xu Xiaochun, , Maoxing Investment Management (Hangzhou), Yang Lijuan , Wang Jianrong, etc. with RMB1.5656 billion.

Global and China Stem Cell Industry Report, 2015-2018 highlights the followings:
20120114.gifClassification, application, industry chain definition, etc. of stem cells;
20120114.gifMajor enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;
20120114.gifPolicies, upstream/midstream/downstream development, etc. of China stem cell industry;
20120114.gifOperation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide.

1. Overview of Stem Cell Industry
1.1 Definition
1.2 Classification and Application
1.3 Industry Chain
1.4 Development Course

2. Global Stem Cell Industry Chain
2.1 Industry Chain Layout of Major Enterprises
2.2 Policy
2.3 Development
2.4 Upstream
2.5 Downstream
2.6 Prospect

3. China Stem Cell Industry Chain
3.1 Development
3.2 Policy
3.3 Upstream
3.4 Midstream
3.5 Downstream

4. Upstream Enterprises
4.1 Cryo-Cell International
4.1.1 Profile
4.1.2 Operation
4.1.3 Cord Blood Business
4.2 Esperite
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Stem Cell Business
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Stem Cell Business
4.3.7 Development Forecast
4.4 Golden Meditech
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Cord Blood Business 
4.4.5 Development Forecast
4.5 LifeCell International
4.5.1 Profile 
4.5.2 Cord Blood Business 
4.6 Cryosite
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Stem Cell Business
4.7 Health & Biotech
4.7.1 Profile 
4.7.2 Operation 
4.8 Tian Qing Stem Cell
4.8.1 Profile 
4.8.2 Operation 
4.8.3 Revenue Structure

5. Midstream and Downstream Enterprises
5.1 Caladrius Biosciences
5.1.1 Profile 
5.1.2 Operation 
5.1.3 Revenue Structure 
5.1.4 R&D and Investment  
5.1.5 Stem Cell Business  
5.2 Mesoblast
5.2.1 Profile 
5.2.2 Operation 
5.2.3 R&D and Investment  
5.2.4 Stem Cell Business  
5.3.1 Profile 
5.3.2 Operation 
5.3.3 Stem Cell Business  
5.4 Beike Biotechnology
5.4.1 Profile 
5.4.2 Stem Cell Business  
5.5 Osiris Therapeutics
5.5.1 Profile 
5.5.2 Operation 
5.5.3 R&D 
5.6 Orthofix International
5.6.1 Profile 
5.6.2 Operation 
5.6.3 Revenue Structure 
5.6.4 R&D 
5.6.5 Stem Cell Business  
5.7 Cytori Therapeutics
5.7.1 Profile 
5.7.2 Operation 
5.7.3 R&D 
5.8 Athersys
5.8.1 Profile 
5.8.2 Operation 
5.8.3 R&D 
5.9 Pluristem Therapeutics
5.9.1 Profile 
5.9.2 R&D and Recent News
5.10 StemCells
5.10.1 Profile 
5.10.2 Operation 
5.10.3 R&D 
5.11 Ocata
5.11.1 Profile 
5.11.2 Operation 
5.11.3 R&D 
5.12 Celgene
5.12.1 Profile 
5.12.2 Operation 
5.12.3 R&D 
5.13 Vitro Biopharma
5.13.1 Profile 
5.13.2 Operation 
5.13.3 R&D 
5.13.4 Stem Cell Business  
5.14 Reneuron
5.14.1 Profile 
5.14.2 Operation 
5.14.3 R&D 
5.15 Tigenix
5.15.1 Profile 
5.15.2 Operation 
5.15.3 R&D 
5.16 Cellular Biomedicine
5.16.1 Profile 
5.16.2 Operation 
5.16.3 R&D 
5.16.4 Stem Cell Business  
5.16.5 Business in China
5.17.1 Profile 
5.17.2 Operation 
5.17.3 Stem Cell Business  
5.18 Opexa Therapeutics
5.19 ZhongKe Biopharm
5.20 Cyagen Biosciences
Classification of Stem Cell 
Overview of Stem Cell Therapy Area (by Disease Type)
Advantages and Disadvantages of Stem Cell Therapy
Source and Application of Adult Stem Cells (by Type)
Stem Cell Industry Chain
Industry Chain Distribution of Major Global Stem Cell Enterprises
Policy Tendency of Human Embryonic Stem Cell Research Worldwide
Stem Cell Products Granted "Orphan Drug" by EU EMEA
Global Authorized Stem Cell Varieties
Top 20 Indications of Global In-research Stem Cell by the end of 2014
Global Stem Cell Products in Late R&D Stage  
Global Stem Cell Market Size and YoY Growth, 2007-2014 
Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2014 
Distribution of Cord Blood-related Research Projects Registered in the US National Institutes of Health, by Nov 17, 2015
Clinical Application of Global Stem Cell Technology (by Disease Type), 2014 
Cord Blood Bank Distribution in Major Countries by the end of 2014
Cord Blood Application in Major Countries
Global Top 10 Death Causes (by Death Toll), 2012
Global Top 10 Death Causes (by Income Group), 2012
Global Top 10 Death Causes in Low-income Countries, 2012
Global Top 10 Death Causes in Low- and Middle-income Countries, 2012
Global Top 10 Death Causes in Middle- and High-income Countries, 2012
Global Top 10 Death Causes in High-income Countries, 2012
Application Prospect of Global Stem Cell
Global Stem Cell Market Size and YoY Growth, 2014-2018E
Some Chinese Stem Cell Clinical Trial Drugs Approved by CFDA
Construction of Chinese Stem Cell Industrialization Bases
China's Stem Cell Industry Policies, 1999-2015
Major Enterprises and Their Stem Cell Business in China Upstream Stem Cell Industry
Major Enterprises and Their Stem Cell Business in China Midstream Stem Cell Industry 
Chinese Stem Cell Medical Market Size and YoY Growth, 2007-2018E
Revenue and Net Income of Cryo-Cell International, FY2010-FY2015
Total Assets, Total Liabilities and Asset-liability Ratio of Cryo-Cell International, FY2010-FY2014
Cord Blood Revenue and % of Total Revenue of Cryo-Cell International, FY2012-FY2015
Revenue and Net Income of Esperite, 2010-2015
Revenue of Esperite (by Business), 2010-2015 
Revenue Structure of Esperite (by Region), 2014 
Stem Cell Storage of Esperite, 2009-2014
Stem Cell Storage Revenue and EBITA of Esperite, 2010-2015 
Operation of Main Subsidiaries of VCANBIO by 2015H1
Revenue and Net Income of VCANBIO, 2010-2015 
Revenue of VCANBIO (by Business), 2011-2015
Revenue of VCANBIO (by Region), 2011-2015
Gross Margin of VCANBIO (by Business), 2011-2015
R&D Costs and % of Total Revenue of VCANBIO, 2011-2015
Fund-raising Investment Projects and Progress of VCANBIO, by Jun 30, 2015
Stem Cell Storage Business of VCANBIO (by Type), 2009-2014
Revenue and Net Income of VCANBIO, 2014-2017E
Revenue and Net Income of Golden Meditech, FY2009-FY2014
Revenue of Golden Meditech (by Business), FY2009-FY2014
Cord Blood Bank Revenue and % of Total Revenue of Golden Meditech, FY2011-FY2014
Cord Blood Bank Gross Profit and Gross Margin of Golden Meditech, FY2011-FY2014
Development Course of Golden Meditech’s Cord Blood Storage Business
Revenue and Net Income of Golden Meditech, FY2014-FY2018E
Development Course of LifeCell International
Revenue and Net Income of Cryosite, FY2011-FY2015
Revenue and EBITDA of Cryosite (by Business), FY2011-FY2014
Equity Structure of Health & Biotech   
Industry Base Distribution of Health & Biotech 
Revenue and Net Income of Health & Biotech, 2012-2014    
Revenue and Net Income of Tian Qing Stem Cell, 2013-2015 
Revenue (by Business) of Tian Qing Stem Cell, 2013-2015 
Subsidiaries of Caladrius Biosciences, by the end of 2014
Revenue and Net Income of Caladrius Biosciences, 2009-2015
Revenue (by Business) of Caladrius Biosciences, 2012-2015
R&D Costs and % of Total Revenue of Caladrius Biosciences, 2009-2014
M & A Course of Caladrius Biosciences, 2009-2014
Revenue and Net Income of Mesoblast, FY2009-FY2015
R&D Costs and % of Total Revenue of Mesoblast, FY2009-FY2015
M&A Course of Mesoblast by the end of 2014
Stem Cell Product R&D Progress of Mesoblast by the end of June 2015
Revenue and Net Income of MEDIPOST, 2011-2014
Adult Stem Cell Drugs and Therapeutic Area of MEDIPOST
Development Course of Beike Biotechnology
Stem Cell Brands and Therapeutic Area of Osiris Therapeutics
Revenue, Net Income and Gross Margin of Osiris Therapeutics, 2011-2015 
R&D Costs and % of Total Revenue of Osiris Therapeutics, 2011-2015 
Revenue, Net Income and Gross Margin of Orthofix International, 2009-2014
Revenue of Orthofix International (by Department), 2011-2015 
R&D Costs and % of Total Revenue of Orthofix International, 2011-2015
Revenue, Net Income and Gross Margin of Cytori Therapeutics, 2010-2015 
Revenue of Cytori Therapeutics (by Region), 2010-2015 
R&D Costs and % of Total Revenue of Cytori Therapeutics, 2010-2015 Revenue and Net Income of Athersys, 2010-2015 
Revenue of Athersys (by Source), 2010-2015 
R&D Costs and % of Total Revenue of Athersys, 2010-2015 
Significant Cooperative Partners and Areas of Athersys
Revenue and Net Income of StemCells, 2011-2015
R&D Costs and % of Total Revenue of StemCells, 2011-2015 
Stem Cell Product R&D, Therapeutic Area and Progress of StemCells by 2015H1
Revenue, Net Income and Gross Margin of Ocata, 2010-2015
R&D Costs and % of Total Revenue of Ocata, 2010-2015
Stem Cell Product R&D, Therapeutic Area and Progress of Ocata by the end of 2014
Revenue, Net Income and Operating Margin of Celgene, 2009-2014
Cellular Therapy R&D Costs and % of Total Revenue of Celgene, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Celgene as of 2014H1
Revenue and Net Income of Vitro Biopharma, FY2009-FY2015
R&D Costs and % of Total Revenue of Vitro Biopharmas, FY2009-FY2015
Stem Cell Brands and Application Fields of Vitro Biopharma
Revenue and Net Income of Reneuron, FY2010-FY2015
R&D Costs and % of Total Revenue of Reneuron, FY2010-FY2015
Stem Cell Products R&D, Therapeutic Area and Progress of Reneuron by the end of 2014
Revenue and Net Income of Tigenix, 2009-2015
Sales of Tigenix (by Region), 2011-2013
R&D Costs and % of Total Revenue of Tigenix, 2012-2015 
Stem Cell Product R&D, Therapeutic Area and Progress of Tigenix by 2015H1
Development Course of Cellular Biomedicine
Revenue and Net Income of Cellular Biomedicine, 2013-2015
R&D Costs and % of Total Revenue of Cellular Biomedicine, 2013-2015 
Stem Cell Product R&D, Therapeutic Area and Progress of Cellular Biomedicine by 2015H1
Revenue and Net Income of SALIAI, 2013-2015

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号